We'll be shorting the heck out of this one tomorrow, it's coming up on everyone's "To FADE" List. There is no partnership, -.25c share loss, history of failed trials in late stage and multiple pending lawsuits. Good Luck to Longs
Btw, the Zacks Investment Research promotion firm no longer has Alnylam at the top of their "short-term" "strong buy" list for their paid subscribers. They noted it was only a "short-term" "strong buy" which of course didn't do anything. We all know these small biotech companies get a lot of pressure from the hedge funds to do a secondary to raise capital and as this company is bleeding 25c share and has never made any profit in it's history it should come as the price falls lower and lower each day on increasing volume.